BioDAOs
Last updated
Last updated
BioDAOs are community-owned scientific research networks. They typically focus on a specific scientific or medical area, and use the power of a globally distributed collective of stakeholders (patients, scientists and biotech builders) to accelerate the R&D process and develop new intellectual property (IP). BioDAO members pool together resources (capital, labor, data) for the mission of the DAO. By sharing resources, these communities can reduce the cost of innovation and the time to commercialization.
BioDAO Benefits:
Rapid Research Funding: BioDAOs raise funding via token sales, and use their treasuries to back and develop biotech projects related to their mission, creating shared ownership of the resulting IP between their members.
No Gatekeeping: BioDAO tokens represent a stake in the DAO's research, granting community members a say in how funds and BioDAO revenue are allocated. Anyone can contribute, which means new biotechnologies aren’t bottlenecked by a handful of traditional funders.
Liquid IP: BioDAOs use Molecule's tokenized to own, license, and transact in IP generated from projects they support. Proceeds from IP and product sales can flow back into a BioDAO's treasury to fund and translate the next generation of R&D, further advancing the BioDAO’s mission.
Key advantages over traditional scientific models:
Capital Efficiency: Pooled resources lower innovation costs
Flexible Work Model: Enable part-time expert contributions
Shared IP Ownership: Incentivize contributions through IP ownership
Open Access: Remove gatekeeping in scientific funding and decision-making
Diversified Portfolio: Bundle many biotech projects simultaneously, reducing risk
Explore BioDAOs in the or track BioDAO-backed science in the
: Funded $8M+ in longevity science, backed by Pfizer Ventures, partnered with Newcastle University.
: Accelerating a cure for 100M+ Long COVID patients. Founded by Rohan Dixit, ex-Stanford Neuroscientist, healthcare entrepreneur and Long COVID survivor.
: Building quantum microscopes to advance bio research. Founded by Clarice D. Aiello, MIT PhD and world-leading Quantum Biology Scientist, and Geoff Anders, Executive Director of Leverage Research.
: Tackling the $1T+ rare disease space by uniting patient families and researcher communities. Founded by Ethan Perlstein, Harvard PhD, rare disease entrepreneur & Y-Combinator alumnus.
: Targeting hair loss; developed DAO-owned provisional patents and consumer products including a Telehealth platform, .
: Advancing brain health, raised over $1.5M, struck a deal with Fission Pharma to tackle mitochondrial dysfunction in neurodegenerative disease.
: Focusing on synthetic biology, raised $2M+ and partnered with Imperial College London.
: Advancing women’s health R&D, funded $500k in translational research, with 14 IP deals pending.
: Advancing the field of cryogenics; $3M raised for the field and established projects with Oxford Cryotechnology and Advanced Neural Biosciences.
: Focusing on psychedelic medicines, having launched , a new platform leveraging psychedelics trials and data.
